Clinical Trial Search

Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml

Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants

Primary: Number of Moderate to Severe Exacerbation (Defined as Requiring Treatment With Systemic Corticosteroids and/or Antibiotics in the Community or Hospital or…

Primary: Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug — 155; 150 milliliters (mL) — p=0.021

Primary: The Number of Participants With Mild Persistent Asthma (Part 1) and COPD (Part 2) With at Least 1 Treatment-emergent Adverse Event — 5; 5; 3; 3 Participants

Primary: FEV1 Percent Change Post-ipratropium — 10.8 percent change — p=0.032

Primary: Subjects With ≥1 Treatment-emergent Adverse Event — 2; 3; 2; 2 Participants

Primary: Change From Baseline in Asthma Control at 18 Months — 1.27; 1.17 score on a scale

Primary: ANALYSIS OF LUNG DEPOSITION - Penetration Index — 0.8; 0.72; 0.69; 0.58 ratio

Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8

Primary: Mean Area Under the Concentration Time Curve Over the Dosing Period (AUC[0-tau]) for FP — 376.9; 573.1; 350.5; 559.1 Picogram hours per milliliter (pg*h/mL)

Primary: Percentage of Participants With COPD Who Rate the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrate Correct Use of the Inhaler at the End of…

Primary: Late Asthmatic Response (LAR) - Smokers: Absolute Change From Saline in Minimum Forced Expiratory Volume in One Second (FEV1) Between 4-10 Hours (Hrs) After Allergen…

Primary: Change in Maximum Forced Expiratory Volume at One Second (FEV1) — 20; 20; 20; 19 percentage of change

Primary: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose — 1.71; 1.79; 1.72; 1.71 L

Primary: Time to First Severe Exacerbation — 43.75; 49.43 Days — p=0.758

Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53

Primary: The Percentage of Participants With Asthma Who Rated the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrated Correct Use of the Inhaler at the…

Primary: The Primary Outcome is the Change in Bronchodilation and Bronchoprotection After Broccoli Sprout Extract — 10.3; 26.7 index

Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L

Primary: Time to Asthma Exacerbation (Mean Number of Exacerbations/Person-year) — 0.37; 0.42 event per person-year — p=0.31

Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage

Primary: Mean Number of Pharmacy Claims by Participants During the Post-Index Period — 2.960; 0.219; 5.491; 0.573 pharmacy claims

Primary: Change in Total Ventilation Volume — 0.154317; -0.13687 Litres

Primary: Percentage Decrease of Sputum Eosinophils From Baseline to End of Therapy (6 Months) — 11.28; 7.07 percentage

Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1

Primary: Number of Par. With Chronic Obstructive Pulmonary Disease (COPD) EXs Requiring Hospitalization That Occurred >21 Days Post-discharge/Physician's Office Visit for a COPD…

Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2

Primary: Rate of Moderate or Severe COPD Exacerbations in Participants With Moderate to Very Severe COPD. — 1.75; 2.11 exacerbations per year — p=0.1042

Primary: Change in Cigarettes Per Day From Baseline to Week 8 and Week 16 — 16.34; 15.39; 9.51; 8.66 cigarettes per day — p=.004